Skip to main content
Erschienen in: Journal of Neuro-Oncology 1/2009

01.01.2009 | Laboratory Investigation - human/animal tissue

Chromosome 1p and 19q deletions in malignant glioneuronal tumors with oligodendroglioma-like component

verfasst von: Hiroaki Takeuchi, Toshihiko Kubota, Ryuhei Kitai, Ken Matsuda, Norichika Hashimoto, Kazufumi Sato

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Malignant glioneuronal tumors (MGNT) are suggested to be a new entity of glioma defined morphologically as any malignant glioma showing immunohistoichemical evidence of neuronal differentiation. We encountered seven cases of MGNT with oligodendroglioma-like component and investigated alternations of chromosome 1p and 19q in these tumors. Seven patients ranged from 33 to 62 years of age, four females and three males. Immunohistochemical study of these tumors was performed using neuronal markers (synaptophysin, neurofilament, β-tubulin, chromogranin A and NeuN), astrocytic marker (GFAP) and Ki-67. We undertook a molecular cytogenetic study of tumor specimens obtained from seven patients using fluorescence in situ hybridization (FISH) with DNA probes mapping to chromosome 1p36, 1q25, 19p13 and 19q13. Histologically, these tumors resembled anaplastic oligodendroglioma. Immunohistochemically, tumor cells were immunoreactive for synaptophysin (7/7), neurofilament (6/7), β-tubulin (5/7), chromogranin A (4/7), NeuN (2/7) and GFAP (7/7). The Ki-67 labeling index ranged from 4.5% to 20.7%. FISH analysis demonstrated either 1p or 19q deletion in all seven cases (100%) and both 1p and 19q deletions in five cases (71%). The 1p deletion was detected in six of seven cases (86%) and 19q deletion was also detected in six (86%). 1p and 19q deletions were present in MGNT, especially those with oligodendroglial components. We suggest that the oligodendroglial-like feature was associated with not only 1p or 19q loss but also differentiation along neuronal cell lines as a factor of favorable prognosis in glial tumors. It is inappropriate to make a diagnosis of oligodendroglioma based only on morphological resemblance to oligodendroglia.
Literatur
1.
Zurück zum Zitat Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2001) Pathology and genetics of tumours of the nervous system. International Agency of Research on Cancer, Lyon Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2001) Pathology and genetics of tumours of the nervous system. International Agency of Research on Cancer, Lyon
5.
Zurück zum Zitat Perry A, Scheithauer BW, Macaulay RJ, Raffel C, Roth KA, Kros JM (2002) Oligodendrogliomas with neurocytic differentiation. A report of 4 cases with diagnostic and histogenetic implications. J Neuropathol Exp Neurol 61:947–955PubMed Perry A, Scheithauer BW, Macaulay RJ, Raffel C, Roth KA, Kros JM (2002) Oligodendrogliomas with neurocytic differentiation. A report of 4 cases with diagnostic and histogenetic implications. J Neuropathol Exp Neurol 61:947–955PubMed
7.
Zurück zum Zitat Takeuchi H, Sato K, Kitai R, Kubota T (2000) Clinicopathologic features of mixed Glio-neuronal tumors in adult. Brain Pathol 10:586 Takeuchi H, Sato K, Kitai R, Kubota T (2000) Clinicopathologic features of mixed Glio-neuronal tumors in adult. Brain Pathol 10:586
9.
Zurück zum Zitat Bello MJ, Leone PE, Vaquero J, de Campos JM, Kusak ME, Sarasa JL et al (1995) Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 64:207–210. doi:10.1002/ijc.2910640311 PubMedCrossRef Bello MJ, Leone PE, Vaquero J, de Campos JM, Kusak ME, Sarasa JL et al (1995) Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 64:207–210. doi:10.​1002/​ijc.​2910640311 PubMedCrossRef
10.
Zurück zum Zitat Deimling A (1995) Shared allelic loss on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 54:91–95 Deimling A (1995) Shared allelic loss on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 54:91–95
11.
Zurück zum Zitat Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, Schramm J et al (1995) Shared allelic loss on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 54:91–95PubMedCrossRef Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, Schramm J et al (1995) Shared allelic loss on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 54:91–95PubMedCrossRef
12.
Zurück zum Zitat Smith JS, Perry A, Borell TJ, Lee HK, O’Fallon J, Hosek SM et al (1999) Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18:4144–4152. doi:10.1038/sj.onc.1202759 PubMedCrossRef Smith JS, Perry A, Borell TJ, Lee HK, O’Fallon J, Hosek SM et al (1999) Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18:4144–4152. doi:10.​1038/​sj.​onc.​1202759 PubMedCrossRef
13.
Zurück zum Zitat Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479. doi:10.1093/jnci/90.19.1473 PubMedCrossRef Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479. doi:10.​1093/​jnci/​90.​19.​1473 PubMedCrossRef
14.
Zurück zum Zitat Intergroup Radiation Therapy Oncology Group Trial 9402, Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714PubMedCrossRef Intergroup Radiation Therapy Oncology Group Trial 9402, Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714PubMedCrossRef
15.
Zurück zum Zitat Smith JS, Perry A, Borell TJ, Lee HK, O’Fallon J, Hosek SM et al (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636–645PubMed Smith JS, Perry A, Borell TJ, Lee HK, O’Fallon J, Hosek SM et al (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636–645PubMed
16.
Zurück zum Zitat Ino Y, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Jhung S et al (2000) Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg 92:983–990PubMed Ino Y, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Jhung S et al (2000) Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg 92:983–990PubMed
17.
Zurück zum Zitat He J, Mokhtari K, Sanson M, Marie Y, Kujas M, Huguet S et al (2001) Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol 60:863–871PubMed He J, Mokhtari K, Sanson M, Marie Y, Kujas M, Huguet S et al (2001) Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol 60:863–871PubMed
18.
Zurück zum Zitat Kraus JA, Lamszus K, Glesmann N, Beck M, Wolter M, Sabel M et al (2001) Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol 101:311–320PubMed Kraus JA, Lamszus K, Glesmann N, Beck M, Wolter M, Sabel M et al (2001) Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol 101:311–320PubMed
19.
Zurück zum Zitat Schleiermacher G, Peter M, Michon J, Hugot JP, Vielh P, Zucker JM et al (1994) Two distinct deleted regions on the short arm of chromosome 1 in neuroblastoma. Genes Chromosom Cancer 10:275–281. doi:10.1002/gcc.2870100409 PubMedCrossRef Schleiermacher G, Peter M, Michon J, Hugot JP, Vielh P, Zucker JM et al (1994) Two distinct deleted regions on the short arm of chromosome 1 in neuroblastoma. Genes Chromosom Cancer 10:275–281. doi:10.​1002/​gcc.​2870100409 PubMedCrossRef
20.
Zurück zum Zitat Weith A, Martinsson T, Cziepluch C, Bruderlein S, Amler LC et al (1998) Neuroblastoma consensus deletion maps to 1p36.1-2. Genes Chromosomes Cancer 1:156–166 Weith A, Martinsson T, Cziepluch C, Bruderlein S, Amler LC et al (1998) Neuroblastoma consensus deletion maps to 1p36.1-2. Genes Chromosomes Cancer 1:156–166
22.
23.
24.
Zurück zum Zitat Daumas-Duport C, Varlet P, Tucker ML, Beuvon F, Cervera P, Chodkiewicz JP (1997) Oligodendrogliomas. Part I: patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J Neurooncol 34:37–59. doi:10.1023/A:1005707203596 PubMedCrossRef Daumas-Duport C, Varlet P, Tucker ML, Beuvon F, Cervera P, Chodkiewicz JP (1997) Oligodendrogliomas. Part I: patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J Neurooncol 34:37–59. doi:10.​1023/​A:​1005707203596 PubMedCrossRef
25.
Zurück zum Zitat Kros JM, Van Eden CG, Stefanko SZ, Waayer-Van Batenburg M, van der Kwast TH (1990) Prognostic implications of glial fibrillary acidic protein containing cell types in oligodendrogliomas. Cancer 66:1204–1212. doi:10.1002/1097-0142(19900915)66:6<1204::AID-CNCR2820660621>3.0.CO;2-APubMedCrossRef Kros JM, Van Eden CG, Stefanko SZ, Waayer-Van Batenburg M, van der Kwast TH (1990) Prognostic implications of glial fibrillary acidic protein containing cell types in oligodendrogliomas. Cancer 66:1204–1212. doi:10.1002/1097-0142(19900915)66:6<1204::AID-CNCR2820660621>3.0.CO;2-APubMedCrossRef
27.
Zurück zum Zitat Dehghani F, Schachenmayr W, Laun A, Korf HW (1998) Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases. Acta Neuropathol 95:493–504. doi:10.1007/s004010050830 PubMedCrossRef Dehghani F, Schachenmayr W, Laun A, Korf HW (1998) Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases. Acta Neuropathol 95:493–504. doi:10.​1007/​s004010050830 PubMedCrossRef
30.
Zurück zum Zitat Wolf HK, Buslei R, Schmidt-Kastner R, Schmidt-Kastner PK, Pietsch T, Wiestler OD et al (1996) NeuN: a useful neuronal marker for diagnostic histopathology. J Histochem Cytochem 44:1167–1171PubMed Wolf HK, Buslei R, Schmidt-Kastner R, Schmidt-Kastner PK, Pietsch T, Wiestler OD et al (1996) NeuN: a useful neuronal marker for diagnostic histopathology. J Histochem Cytochem 44:1167–1171PubMed
Metadaten
Titel
Chromosome 1p and 19q deletions in malignant glioneuronal tumors with oligodendroglioma-like component
verfasst von
Hiroaki Takeuchi
Toshihiko Kubota
Ryuhei Kitai
Ken Matsuda
Norichika Hashimoto
Kazufumi Sato
Publikationsdatum
01.01.2009
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 1/2009
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-008-9690-6

Weitere Artikel der Ausgabe 1/2009

Journal of Neuro-Oncology 1/2009 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.